🇺🇸 FDA
Pipeline program

Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet

S095031-178

Phase 3 small_molecule active

Quick answer

Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet for Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS) is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials